US20190144510A1 - Modified antimicrobial peptide derived from an arginine-rich domain - Google Patents

Modified antimicrobial peptide derived from an arginine-rich domain Download PDF

Info

Publication number
US20190144510A1
US20190144510A1 US16/303,464 US201716303464A US2019144510A1 US 20190144510 A1 US20190144510 A1 US 20190144510A1 US 201716303464 A US201716303464 A US 201716303464A US 2019144510 A1 US2019144510 A1 US 2019144510A1
Authority
US
United States
Prior art keywords
peptide
arginine
antimicrobial peptide
hbcard
antimicrobial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/303,464
Other languages
English (en)
Inventor
Chiaho Shih
Heng-Li Chen
Pei-Yi Su
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20190144510A1 publication Critical patent/US20190144510A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A01N37/46—N-acyl derivatives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/40—Viruses, e.g. bacteriophages
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Definitions

  • Antibiotics have been used for the treatment of bacterial infection for more than 60 years. Recently, the increasing number of antibiotics-resistant bacteria has become a major threat to public health. The development of new antibiotics for clinical treatment is an urgent need.
  • Antimicrobial peptides (AMPs) from various species can serve as a defense weapon of the host against pathogenic microbes. Because they can kill bacteria and fungi via different mode of actions, they have been considered as potential candidates to overcome the problem of antibiotic-resistance.
  • an antimicrobial peptide contains 2 to 20 variable domains, each variable domain is a sequence of 2 to 20 consecutive basic amino acids, wherein (a) the variable domains are separated from each other by a variable linker, (b) the variable linker can have 1 to 20 any amino acids other than two or more consecutive basic amino acids, and (c) the peptide has no more than 100 amino acids.
  • peptide has at least 3 or 4 variable domains.
  • the peptide can have a C-terminal cysteine.
  • at least one of the basic amino acids in the variable domains is an arginine.
  • all of the basic amino acids in each variable domain in the peptide can be arginine residues.
  • at least one variable domain in the antimicrobial peptide has a lysine.
  • at least one variable domain has a histidine.
  • the peptide can have a cyclic structure.
  • At least one of the basic amino acids in the peptide can be a chemically-modified amino acid.
  • the chemically-modified amino acid is a D-amino acid, e.g., D-arginine.
  • the variable domains and the variable linkers can be derived from the arginine-rich domain of a hepadnavirus core protein (HBcARD).
  • the HBcARD contains a sequence from residue 147 to the C-terminal residue of a hepadnavirus core protein.
  • Each variable domain in the peptide can have three or four arginine residues and each variable linker in the peptide can have 2 to 4 amino acids.
  • the peptide can exhibit a broad spectrum antimicrobial activity against a gram-positive bacterium, gram-negative bacterium, fungus, parasite, or virus.
  • the antimicrobial peptide contains a consensus sequence selected from the group consisting of:
  • each of X 1 , X 4 , and X 7 individually, is a variable domain, and each of X 2 , X 3 , X 5 , and X 6 , individually, is any amino acid or absent.
  • Each variable domain is a sequence of 2 to 20 consecutive basic amino acids.
  • the peptide can have a consensus sequence selected from the group consisting of:
  • each of X 1 , X 3 , X 6 , and X 9 is a variable domain, and each of X 2 , X 4 , X 5 , X 7 , X 8 , and X 10 , individually, is any amino acid or absent.
  • the antimicrobial peptide contains a sequence selected from the group consisting of:
  • the antimicrobial peptide can contain the sequence of RRRGRSPRRRTPSPRRRRSQSPRRRRSC (SEQ ID NO: 7), in which each of the arginine residues in the sequence is L-arginine.
  • the peptide can have the sequence of RRRGRSPRRRTPSPRRRRSQSPRRRRSC (SEQ ID NO: 7), in which at least one of the arginine residues in the sequence is D-arginine.
  • the antimicrobial peptide contains the sequence of rRrGRSPrRrTPSPrRrRSQSPrRrRSC (SEQ ID NO: 7), in which R is L-arginine and r is D-arginine.
  • the peptide can contain the sequence of RrRGRSPRrRTPSPRrRrSQSPRrRrSC (SEQ ID NO: 7), in which R is L-arginine and r is D-arginine.
  • the antimicrobial peptide can include the sequence of RRRGRPRRRPPRRRRQPRRRRC (SEQ ID NO: 9), in which at least one of the arginine residues (e.g., 20%, 30%, 40%, or 50% of the arginine residues) in the sequence is D-arginine.
  • the sequence can be rRrGRPrRrPPrRrRQPrRrRC (SEQ ID NO: 9), in which R is L-arginine and r is D-arginine.
  • the antimicrobial peptide further contains a non-HBcARD peptide (e.g., an affinity tag, a signal sequence, a ligand, or another antimicrobial peptide or fragment thereof).
  • the non-HBcARD peptide can be a poly-histidine or an analog thereof.
  • the peptide has a sequence selected from the group consisting of:
  • an antimicrobial peptide conjugate which contains the antimicrobial peptide disclosed herein and a non-peptide moiety.
  • composition in yet another aspect, includes the antimicrobial peptide or the antimicrobial conjugate, and a pharmaceutically acceptable carrier.
  • Also contemplated herein is a method of treating an infection in a subject in need thereof.
  • the method includes administering to the subject an antimicrobial peptide, an antimicrobial peptide conjugate, or a pharmaceutical composition described herein.
  • FIG. 1 includes two sets of sequence alignments of HBcARD domains.
  • HBcARD sequences are highly conserved among human (SEQ ID NO: 6), wooly monkey (SEQ ID NO: 18), ground squirrel (SEQ ID NO: 19), woodchuck (SEQ ID NO: 20), and bat (SEQ ID NO: 21).
  • B There are also four positive charge clusters separated in the HBc C-terminus of duck (SEQ ID NO: 22), heron (SEQ ID NO: 23), parrot (SEQ ID NO: 24), Ross's goose (SEQ ID NO: 25) and snow goose hepatitis B virus (SEQ ID NO: 26).
  • FIG. 2 is a set of graphs showing comparison of serum resistance between L- and D-HBcARD peptides.
  • Peptides L-HBcARD and D-HBcARD were incubated with MBC buffer (10 mM sodium phosphate and 50 mM sodium chloride, pH 7.2) containing 5% fetal bovine serum (A), 5% mouse serum (B) or human serum (male and female) (C) at 37° C. for 3 hours. The amounts of peptides were determined using SDS PAGE electrophoresis and green angel staining.
  • D Peptide D-HBcARD exhibited 10,000-fold higher potency than that of L-HBcARD in MBC assay.
  • Peptides (L-HBcARD and D-HBcARD) were incubated with S. aureus ATCC19636 with or without 5% mouse serum at 37° C. for 3 hours.
  • the antimicrobial activity was determined by colony formation assay. ***P ⁇ 0.0001.
  • FIG. 3 is a graph showing comparison of hemolytic effect between L- and D-HBcARD peptides. Human red blood cells were incubated with different concentrations of the peptides. Hemolysis is presented as the percentage of Triton X-100-induced hemolysis. ***P ⁇ 0.0001.
  • FIG. 4 is a set of graphs showing comparison of in vivo protection activities between L- and D-form HBcARD peptides in a mouse sepsis model infected with S. aureus .
  • A Three week-old ICR mice were inoculated with S. aureus (4 ⁇ 10 6 CFU/mouse) and i.p. injected with PBS, L-HBcARD, or D-HBcARD at 2 hours post-inoculation. Each group contained ten mice.
  • B and
  • Three week-old ICR mice were immunized with L- and D-HBcARD peptides (5 mg/kg), respectively, at day 0, 3 and 6. On day 14, the mice were inoculated with S.
  • mice were treated with PBS in parallel as a control. Each group of animals contained five mice. *P ⁇ 0.05; ***P ⁇ 0.0001; ns, no significance.
  • FIG. 5 is a graph showing in vivo protection efficacies of various modified HBcARD peptides at different doses in an ICR mouse sepsis model.
  • FIG. 6 is a graph showing in vivo protection efficacies of 150-177C and 150-177Q peptides in a BALB/c mouse lung infection model. Colistin-resistant A. baumannii was inoculated via intra-tracheal route.
  • FIG. 7 is a set of graphs showing lower in vivo toxicity of HBcARD peptide D-150-177C in comparison with polymyxin B.
  • male ICR mice (5 mice/group) were ip. injected with different doses of D-150-177C peptide (20-80 mg/kg) and polymyxin B (50 mg/kg), respectively.
  • A The survival rates of all groups were monitored for 7 days.
  • B Serum samples collected from mice treated with D-150-177C and polymyxin B were determined for alanine aminotransferase activity (ALT) at day 1. The dash line represents the mean of ALT value (45 U/L) of ICR mice (Charles River Laboratories).
  • FIG. 9 is a graph showing that deletion of serine and threonine residues from peptide DL-150-177C improved the in vivo protection efficacies at different doses in a mouse sepsis model.
  • an antimicrobial peptide contains at least two (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) variable domains.
  • the variable domains are in tandem and each separated from another by a variable linker.
  • the antimicrobial peptide can have a maximum length of 100 amino acids (e.g., less than 10, 10, 14, 15, 20, 21, 22, 25, 28, 30, 35, 37, 40, 45, 47, 50, 55, 57, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids).
  • the peptide has a C-terminal cysteine.
  • variable domains are a sequence of at least two (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) consecutive basic amino acids, e.g., arginine, histidine, and lysine.
  • Each variable domain can contain a sequence of identical basic amino acids or different basic amino acids.
  • the antimicrobial peptides can contain 2 to 20 identical or different variable domains, each being X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 (SEQ ID NO: 27), wherein each of X 1 -X 20 , individually, is an arginine, histidine, or lysine (natural or chemically modified) and any of X 3 -X 20 can be present or absent.
  • each variable domain can have 2 to 10 basic amino acids.
  • At least one variable domain in the peptide consists solely of arginine residues. In another embodiment, all of the variable domains in the peptide contain only arginine residues. Alternatively, the peptide can contain at least one variable domain that has one or more histidine or lysine residues.
  • Each variable linker has at least one amino acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) and can contain any amino acid. It cannot have two or more consecutive basic amino acids.
  • amino acid refers to any of the 20 standard amino acids (i.e., alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine).
  • the term can also refer to a non-standard, non-proteinogenic, or chemically-modified amino acid, or an amino acid analog.
  • An amino acid can be in the L- or D-form stereoisomer.
  • basic amino acid refers to arginine, lysine, or histidine, the L- or D-form thereof, or an analog thereof.
  • Non-standard amino acids include selenocysteine, pyrrolysine, N-formylmethionine, non-proteinogenic amino acids, amino acid analogs, and chemically-modified amino acids.
  • a chemically-modified amino acid or amino acid analog typically has a different side chain from its naturally-occurring counterpart Amino acid analogs and methods of incorporating them into a polypeptide are known in the art. See, e.g., Nguyen et al., Biochemica et Biophysica Acta 1808 (2011), 2297-2303; Knappe, Antimicrobial Agents and Chemotherapy 54(9) 2010, 4003-4005; U.S. Pat. Nos. 7,879,979; 5,972,940; 8,835,162; and US20080199964.
  • Amino acid analogs are also commercially available. Amino acid analogs can be incorporated in the antimicrobial peptide to improve its stability, bioavailability, pharmacokinetics, tissue distribution, safety, tolerability, and/or efficacy.
  • any of the antimicrobial peptides described herein can contain one or more residues that are not one of the twenty standard amino acids.
  • one or more e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 2%, 3%, 5%, 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%
  • the basic amino acids in the variable domains or in the entire antimicrobial peptide can be a D-form of natural arginine, lysine, or histidine, or an analog of natural arginine, lysine, or histidine.
  • the antimicrobial peptide can be derived from the arginine-rich domain of a hepadnavirus core protein (HBcARD).
  • HBcARD refers to a highly conserved arginine-rich C-terminal region of a core protein (HBc). See, FIG. 1 .
  • the HBc can be a mammalian HBc or an avian HBc.
  • a mammalian HBc can be human HBc, woolly monkey HBc, ground squirrel HBc, woodchuck HBc, and bat HBc.
  • An avian HBc can be a duck, heron, parrot, Ross's goose, or snow goose HBc.
  • the HBc can be from a hepadnavirus of any genotype.
  • the antimicrobial peptide can include a fragment of the HBcARD or a variant thereof (e.g., containing one or more amino acid substitutions, deletions, or insertions).
  • the variable domains and the linkers can be derived from an HBcARD.
  • the sequence between any two arginine repeats in an HBcARD or a variant thereof can be used as a linker.
  • the antimicrobial peptide contains a consensus sequence selected from the group consisting of:
  • each of X 1 , X 4 , and X 7 individually, is a variable domain, and each of X 2 , X 3 , X 5 , and X 6 , individually, is any amino acid or absent.
  • Each variable domain is a sequence of 2 to 20 consecutive basic amino acids.
  • the peptide can have a consensus sequence selected from the group consisting of:
  • each of X 1 , X 3 , X 6 , and X 9 is a variable domain, and each of X 2 , X 4 , X 5 , X 7 , X 8 , and X 10 , individually, is any amino acid or absent.
  • the antimicrobial peptide can be a fusion or chimeric peptide that further contains a non-HBcARD peptide.
  • a non-HBcARD peptide is not derived from any HBcARD and does not contain at least two variable domains connected by a linker as described above.
  • a non-HBcARD peptide can be a peptide derived from another source (e.g., from a protein other than an HBcARD), an engineered peptide (e.g., another antimicrobial peptide), an affinity tag (e.g., a FLAG, poly-His, Myc, HA, CBP, HBH, or V5 tag), a signal sequence (e.g., a leader sequence or a localization signal), or a ligand (e.g., a receptor ligand).
  • another source e.g., from a protein other than an HBcARD
  • an engineered peptide e.g., another antimicrobial peptide
  • an affinity tag e.g., a FLAG, poly-His, Myc, HA, CBP, HBH, or V5 tag
  • a signal sequence e.g., a leader sequence or a localization signal
  • ligand e.g., a receptor ligand
  • the antimicrobial peptide can have up to 100 amino acids and contain a sequence selected from the group consisting of:
  • the antimicrobial peptide can have one or more modified amino acids.
  • one or more of the basic amino acids in the variable domains or in the entire antimicrobial peptide can be a D-form of natural arginine, lysine, or histidine, or an analog of natural arginine, lysine, or histidine.
  • Any of the above-described sequences or consensus sequences can be at the N- or C-terminus of the antimicrobial peptide.
  • the antimicrobial peptide described herein can also be conjugated to a non-peptide moiety at the N- or C-terminus to form a peptide conjugate.
  • a non-peptide moiety can be a polymer (e.g., a polyethylene glycol polymer), oligosaccharide, lipid, glycolipid, solid support (e.g., a bead or nanoparticle), small molecule drug, biotin, nucleic acid molecule, antibody, vitamin, carrier protein (e.g., KLH, BSA, or OVA), or detectable label (e.g., fluorescent, radioactive, or enzymatic label).
  • the peptide conjugate also exhibits an antimicrobial activity. Methods of generating peptide conjugates are known in the art.
  • the antimicrobial peptide or peptide conjugate described herein can be mixed with a pharmaceutically acceptable carrier to form a pharmaceutical composition.
  • composition can be formulated with a pharmaceutically acceptable carrier such as a phosphate buffered saline, a bicarbonate solution, and/or an adjuvant.
  • a pharmaceutically acceptable carrier such as a phosphate buffered saline, a bicarbonate solution, and/or an adjuvant.
  • Suitable pharmaceutical carriers and diluents, as well as pharmaceutical necessities for their use, are known in the art.
  • This composition may be prepared as an injectable, liquid solution, emulsion, or another suitable formulation.
  • compositions described above may be administered by intranasal inhalation, topical application, or parenteral routes, e.g., intravenous injection, subcutaneous injection or intramuscular injection.
  • parenteral routes e.g., intravenous injection, subcutaneous injection or intramuscular injection.
  • binders and carriers may include, for example, polyalkalene glycols or triglycerides.
  • Oral formulations may include normally employed incipients such as pharmaceutical grades of saccharine, cellulose, magnesium carbonate and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders.
  • compositions can be administered to a subject (e.g., a human, another mammal, or a laboratory animal) to treat a microbial infection or to inhibit growth of a microbe in the subject.
  • the composition can be used to treat an infection caused by a Gram-positive or Gram-negative bacteria, fungus, parasite, or virus, e.g., Pseudomonas aeruginosa, Klebsiella pneumoniae, Shigella dysenteriae, Escherichia coli, Staphylococcus aureus, Acinetobacter baumannii, Clostridium Difficile, Candida, Aspergillus, Blastomyces, Cryptococcus neoformans, Cryptococcus gattii, Coccidioides, Histoplasma, Pneumocystis jirovecii , ringworm, Sporothrix, Exserohilum , or Cladosporium.
  • HBV hepatitis B virus
  • HBc hepatitis B virus core protein
  • ARD arginine-rich domain
  • HBcARD peptides are highly conserved in the hepadnaviruses of different species.
  • To improve the antimicrobial efficacy of HBcARD we compared the sequences and antimicrobial activities of various HBcARD peptides of mammalian, rodent, and avian hepadnaviruses.
  • HBcARD peptide of human hepadnaviruses displayed the strongest antimicrobial activity.
  • HBcARD peptides of various hepadnaviruses including human (AAP31571.1), wooly monkey (AA074859.1), ground squirrel (AAB08031.1), woodchuck (AAA46761.1), bat (AGT17576.1), duck (AA049490.1), heron (AAA45737.1), parrot (AFY97786.1), Ross's goose (AAR89928.1) and snow goose (AAD22001.1). See FIG. 1 .
  • HBcARD peptides of other mammalian hepadnaviruses contained four clustering arginine-rich domains. While the sequence homology of HBcARD peptides between avian and mammalian hepadnaviruses was low, they both contained four highly positive-charged domains. To compare their respective antimicrobial activities, we determined the minimal bactericidal concentrations of four HBcARD peptides derived from bat, woodchuck, duck and heron hepadnaviruses.
  • peptides derived from bat and woodchuck hepadnaviruses exhibited potent antimicrobial activity comparable to that from human hepatitis B virus. See Table 2.
  • peptides derived from avian hepadnaviruses displayed lower antimicrobial activity. Because HBcARD peptides from human HBV is shorter in length (147-183; 37 amino acids), we focused on this peptide in our subsequent modification and optimization experiments.
  • L- and D-HBcARD peptides (37-mer) were tested side-by-side against a wide variety of bacteria, including P. aeruginosa, K pneumoniae, A. baumannii, E. coli, S. dysenteriae and S. aureus .
  • MBC 2.3-4.6 mg/L
  • K. pneumoniae K. pneumoniae
  • the antimicrobial activity of D-HBcARD peptide against E. coli and S. dysenteriae was decreased from 18.4 to 73.6 mg/
  • D-HBcARD peptide was able to achieve a much higher survival rate (60% for 5 mg/kg dose, and 100% for 10 mg/kg dose). See FIG. 4 , A. These results indicated that the in vivo efficacy of HBcARD can be improved by the D-arginine replacement strategy (P ⁇ 0.0001).
  • mice immunized with PBS and treated with PBS showed a mortality near 80% within 24 hours after bacterial challenge (P ⁇ 0.05). Seven days post-inoculation, all mice treated with L- and D-HBcARD (10 mg/kg) survived bacterial challenge, irrespective of the prior immunization with or without D-HBcARD. See FIG. 4 , C. Therefore, prior immunizations with either D-form or L-form peptides induced no neutralization activity against the in vivo antimicrobial activity of subsequent treatments with HBcARD peptides.
  • MBC Minimal bactericidal concentrations (MBC) of modified HBcARD peptides against various Gram-negative and Gram-positive bacteria
  • MBC MBC 150- 150- 150- 157- 164- Bacteria strains 177C 177Q 171C 177C 177C Gram-negative P. aeruginosa ATCC9027 2 — — — — — P. aeruginosa 2 — — — — ATCC27853
  • baumannii ATCC45530 0.5 — — — — — A. baumannii ATCC46709 1 — — — — Gram-positive S. aureus ATCC19636 2 ND ND ND ND —, not determined; ND, no detectable antimicrobial activity
  • mice were intra-tracheally inoculated with colistin-resistant A. baumannii TCGH 46709 (3.4 ⁇ 10 8 cfu/mouse). These lung-infected mice were ip. treated with colistin (5 mg/kg/day) or D-150-177C (5 and 10 mg/kg/day), respectively. All mice treated with colistin died at 60 hours post-inoculation with drug-resistant A. baumannii . See FIG. 6 . In contrast, there was a dose-dependent protection effect from D-150-177C. A significant difference was observed when the mice were treated with 10 mg/kg/day of D-150-177C peptide (p ⁇ 0.05). See FIG. 6 .
  • mice When the doses were increased to 60 and 80 mg/kg, survival rates of mice were decreased to 80% and 40%, respectively. See, FIG. 7 , A. Liver injury can be detected by the serum ALT level. Mice treated with D-150-177C in the dose range of 20 to 40 mg/kg showed a higher ALT level than polymyxin B, but the p value is insignificant. See FIG. 7 , B. The ALT levels of mice treated with 60 mg/kg were significantly higher than those treated at 20 mg/kg polymyxin B (p ⁇ 0.01). See FIG. 7 , B.
  • the 28-mer peptide D-150-177C contains a total of 14 L-arginines substituted with 14 D-arginines. See Table 1 and FIG. 6 . D-arginine is far more expensive than L-arginine. To reduce the cost of peptide synthesis, we compared the in vivo protection efficacies between peptides containing complete or partial D-arginine substitution. See Table 1 and FIG. 8 . Peptide DL-150-177C is only partially D-arginine substituted, and exhibited very similar protection efficacy to all-D-arginine substituted peptide D-150-177C (100% substitution). See FIG. 8 . In contrast, the protection efficacy of peptide LD-150-177C (also partially substituted) appeared to be less than DL-150-177C. See FIG. 8 .
  • HBcARD peptides were tested using a number of bacterial strains, including Pseudomonas aeruginosa Migula strains (ATCC 27853, ampicillin-resistant and ATCC 9027, ampicillin-resistant), Klebsiella pneumoniae strain (ATCC 13884), Shigella dysenteriae Xen27 (Caliper Co.), Escherichia coli strain (ATCC 25922), Staphylococcus aureus subsp.
  • Pseudomonas aeruginosa Migula strains ATCC 27853, ampicillin-resistant and ATCC 9027, ampicillin-resistant
  • Klebsiella pneumoniae strain ATCC 13884
  • Shigella dysenteriae Xen27 Caliper Co.
  • Escherichia coli strain ATCC 25922
  • Staphylococcus aureus subsp Staphylococcus aureus subsp.
  • TCGH 45530 and TCGH 46709 Clinical isolates TCGH 45530 and TCGH 46709 were obtained from Tzu-Chi Buddhist General Hospital (TCGH) in Taiwan, and were identified using the Vitek system (Biomerieux Vitek, Inc., Hazelwood, Mo., USA). See Chang et al. (2012), J Microbiol Immunol Infect 45:37-42 doi:10.1016/j.jmii.2011.09.019.
  • L- and D-HBcARD peptides were purchased from Yao-Hong Biotechnology Inc. (Taipei, Taiwan). Antimicrobial activity was determined as described. See, Chen et al., 2013. Briefly, bacteria were grown in MH broth (Difco) to mid-logarithmic phase at 37° C., and were diluted to 10 6 CFU (colony formation unit)/ml in phosphate buffer (10 mM sodium phosphate and 50 mM sodium chloride, pH 7.2). Peptides were serially diluted in the same buffer. Fifty microliters ( ⁇ l) of bacteria were mixed with fifty ⁇ l of peptides at varying concentrations, followed by incubation at 37° C. for 3 hours without shaking.
  • CFU colony formation unit
  • MBC minimal bactericidal concentration
  • L- and D-HBcARD peptides (0.5 nmol) were mixed with MBC buffer in the presence or absence of 5% serum collected from bovine, mouse and human origins. After incubation at 37° C. for 3 hours, the amounts of peptides surviving the protease digestion were determined by SDS-PAGE electrophoresis and staining with Green Angel. The images were quantified using image J software and the intensities were normalized with the no serum control.
  • S. aureus ATCC19636 strain (10 6 CFU/ml) at 37° C. for three hours. Bacteria were plated on MH agar and the antimicrobial activity was determined by colony formation.
  • the hemolytic activities of peptides were determined by hemolysis against human red blood cells (hRBCs).
  • Human blood was obtained in EDTA-containing tube and was centrifuged at 450 g for 10 min. The pellet was washed three times with PBS buffer, and a solution of 10% hRBCs was prepared.
  • hRBCs solution was mixed with serial dilutions of peptides in PBS buffer, and the reaction mixtures were incubated for 1 h at 37° C. After centrifugation at 450 g for 10 min, the percentage of hemolysis was determined by measuring the absorbance at the wavelength of 405 nm of the supernatant. Blank and 100% hemolysis were determined in PBS buffer and in the presence of 1% Triton X-100, respectively.
  • mice Three-week old male ICR mice (19 to 21 g) were purchased from BioLASCO (Taiwan). To test the in vivo protection efficacy of the HBcARD peptides, all mice were inoculated intraperitoneally with S. aureus ATCC 19636 (4 ⁇ 10 6 CFU/mouse). HBc147-183 (L- or D-HBcARD) or the PBS control was administered intraperitoneally at 2 hours after bacterial inoculation, respectively. Each group contained 10 mice. Mortality was monitored daily for 7 days following the bacterial inoculation.
  • mice were immunized three times with 0.2 ml of L- and D-HBcARD peptides (5 mg/kg) at day 0, 3, 6, respectively. Immunized mice were inoculated with S. aureus ATCC 19636 (4 ⁇ 10 6 CFU/mouse) at day 14, and were administered with 0.2 ml of PBS, or L- and D-HBcARD peptide (10 mg/kg) one-hour postinoculation. Another group of mice received the identical protocol with PBS as a control. Each group contained 5 mice. Mortality was monitored daily for 7 days following the bacterial inoculation.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
US16/303,464 2016-05-27 2017-05-25 Modified antimicrobial peptide derived from an arginine-rich domain Abandoned US20190144510A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662342415P 2016-05-27 2016-05-27
PCT/US2017/034489 WO2017205631A1 (en) 2016-05-27 2017-05-25 Modified antimicrobial peptide derived from an arginine-rich domain

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/034489 A-371-Of-International WO2017205631A1 (en) 2016-05-27 2017-05-25 Modified antimicrobial peptide derived from an arginine-rich domain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/932,372 Continuation US20210101939A1 (en) 2016-05-27 2020-07-17 Modified antimicrobial peptide derived from an arginine-rich domain

Publications (1)

Publication Number Publication Date
US20190144510A1 true US20190144510A1 (en) 2019-05-16

Family

ID=60411947

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/303,464 Abandoned US20190144510A1 (en) 2016-05-27 2017-05-25 Modified antimicrobial peptide derived from an arginine-rich domain
US16/932,372 Pending US20210101939A1 (en) 2016-05-27 2020-07-17 Modified antimicrobial peptide derived from an arginine-rich domain

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/932,372 Pending US20210101939A1 (en) 2016-05-27 2020-07-17 Modified antimicrobial peptide derived from an arginine-rich domain

Country Status (14)

Country Link
US (2) US20190144510A1 (ja)
EP (1) EP3464329A4 (ja)
JP (1) JP7161263B6 (ja)
KR (1) KR102530478B1 (ja)
CN (1) CN109641938A (ja)
AU (1) AU2017270201A1 (ja)
BR (1) BR112018074478A2 (ja)
CA (1) CA3024873A1 (ja)
IL (1) IL263086A (ja)
MX (1) MX2018014490A (ja)
SG (1) SG11201809928VA (ja)
TW (1) TWI635095B (ja)
WO (1) WO2017205631A1 (ja)
ZA (1) ZA201807763B (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023034481A1 (en) * 2021-09-01 2023-03-09 Aimmax Therapeutics, Inc. Peptides with antimicrobial activities
US11713341B1 (en) 2022-06-17 2023-08-01 Vestaron Corporation Antimicrobial NCR13 variant peptides

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102544102B1 (ko) * 2021-11-05 2023-06-19 주식회사 레메디 상처 치료 및 항염증 활성을 가지는 펩타이드 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060595A (en) * 1996-09-03 2000-05-09 The General Hospital Corporation Inhibition of viral replication
WO2014124047A1 (en) * 2013-02-06 2014-08-14 Academia Sinica Antimicrobial peptides derived from hepatitis b virus core protein arginine-rich domain

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060595A (en) * 1996-09-03 2000-05-09 The General Hospital Corporation Inhibition of viral replication
WO2014124047A1 (en) * 2013-02-06 2014-08-14 Academia Sinica Antimicrobial peptides derived from hepatitis b virus core protein arginine-rich domain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chen et al. (PLOS Pathogen; June 2013, Vol 9, Issue 6 e1003425) *
UniprotKB-A0A165YEV4 (<https://www.uniprot.org/uniprot/A0A165YEV4> 7/6/16) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023034481A1 (en) * 2021-09-01 2023-03-09 Aimmax Therapeutics, Inc. Peptides with antimicrobial activities
US11713341B1 (en) 2022-06-17 2023-08-01 Vestaron Corporation Antimicrobial NCR13 variant peptides

Also Published As

Publication number Publication date
BR112018074478A2 (pt) 2019-03-19
TW201808985A (zh) 2018-03-16
ZA201807763B (en) 2020-10-28
EP3464329A4 (en) 2020-08-26
KR20190001954A (ko) 2019-01-07
TWI635095B (zh) 2018-09-11
SG11201809928VA (en) 2018-12-28
WO2017205631A1 (en) 2017-11-30
JP7161263B2 (ja) 2022-10-26
JP2019523220A (ja) 2019-08-22
US20210101939A1 (en) 2021-04-08
MX2018014490A (es) 2019-06-24
KR102530478B1 (ko) 2023-05-10
JP7161263B6 (ja) 2023-03-20
AU2017270201A1 (en) 2018-11-29
IL263086A (en) 2018-12-31
EP3464329A1 (en) 2019-04-10
CA3024873A1 (en) 2017-11-30
CN109641938A (zh) 2019-04-16

Similar Documents

Publication Publication Date Title
US20210101939A1 (en) Modified antimicrobial peptide derived from an arginine-rich domain
US9580472B2 (en) Anti-microbial peptides and methods of use thereof
JP2001520631A (ja) 抗真菌性ペプチド
WO2000012542A2 (en) Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties
Sharma et al. Short antimicrobial peptides
JP2004514644A (ja) 抗菌化合物および処方物
AU2019245369A1 (en) Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US11046730B2 (en) Antimicrobial compositions
US10752657B2 (en) Antimicrobial peptides derived from hepatitis B virus core protein arginine-rich domain
KR101341210B1 (ko) 신규한 항균 펩타이드 및 이의 용도
KR20180052178A (ko) 흰점박이꽃무지에서 유래한 항균 펩타이드 프로테티아마이신 1 및 그의 조성물
US7262163B2 (en) Short amphipathic peptides with activity against bacteria and intracellular pathogens
Cardoso et al. Peptides containing d-amino acids and retro-inverso peptides: general applications and special focus on antimicrobial peptides
Zhong et al. Study on the effects of different dimerization positions on biological activity of partial d-Amino acid substitution analogues of Anoplin
Húmpola et al. Biological and structural effects of the conjugation of an antimicrobial decapeptide with saturated, unsaturated, methoxylated and branched fatty acids
Ouyang et al. Improving the antimicrobial performance of amphiphilic cationic antimicrobial peptides using glutamic acid full-scan and positive charge compensation strategies
JPH10508576A (ja) 抗真菌性ペプチド
US11021529B2 (en) Antimicrobial constructs and uses thereof
KR20170053879A (ko) 벼메뚜기에서 유래한 항균 펩타이드 옥시야신-1 및 그의 조성물
JP2004534084A (ja) 抗菌ペプチド
KR20170131909A (ko) 벼메뚜기에서 유래한 항균 펩타이드 옥시야신-3 및 그의 조성물
KR101624688B1 (ko) 신규한 락토페리신 유사 항진균 펩타이드 및 그의 조성물
RU2813626C1 (ru) Модифицированный эндолизин и антибактериальные композиции на его основе для лечения инфекций, вызванных бактериями Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli
US20240010693A1 (en) Peptides from human b-casein that have anti-bacterial activity
WO2020065595A1 (es) Lipopeptidos cortos con actividad antimicrobiana contra bacterias gram negativas y gram positivas

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION